CTC-Guided EGFR Inhibitor Therapy Achieves 14-Month Response in Metastatic Hepatocellular Carcinoma
Key Insights
A 52-year-old woman with metastatic hepatocellular carcinoma (search) showed circulating tumor cells with EGFR (search) mutations (exon 19 deletion and L858R), leading to targeted therapy selection.
EGFR (search) tyrosine kinase inhibitors including erlotinib, afatinib, and osimertinib achieved partial response in lung metastases with treatment benefit lasting 14 months.
The case demonstrates potential for CTC molecular profiling to guide personalized treatment in HCC (search), where traditional tissue biopsy is often limited by bleeding risk.
A novel case report demonstrates how molecular profiling of circulating tumor cells (CTCs) successfully guided targeted therapy selection in a patient with treatment-refractory hepatocellular carcinoma (search) (HCC (search)), achieving a sustained clinical response for 14 months.
The 52-year-old woman presented to Taipei Veterans General Hospital in May 2018 with stage IV hepatitis B-related HCC (search), including multiple liver tumors and lung metastases. Her α-fetoprotein levels were markedly elevated at 12,154 ng/ml, and she was positive for hepatitis B surface antigen with a viral load of 284,000 IU/ml.
Treatment-Refractory Disease Prompts CTC Analysis
Between May 2018 and December 2021, the patient underwent extensive treatment including Y90 radioembolization, transarterial chemoembolization, bevacizumab and atezolizumab, sorafenib, lenvatinib, fluorouracil and oxaliplatin chemotherapy, pembrolizumab, cabozantinib, and ramucirumab. All systemic therapies resulted in a best response of stable disease according to Response Evaluation Criteria in Solid Tumors (version 1.1).
Given the refractory nature of the disease, researchers performed CTC molecular investigation in January 2022. The analysis involved isolating 2.5 × 10⁵ peripheral blood mononuclear cells from 125 μL of peripheral blood, followed by immunostaining with specific antibodies for CTC identification and phenotype analysis.
EGFR Mutations Detected in CTCs
The CTC evaluation revealed positive staining for EGFR (search) exon 19 deletion at 24.7% in the first investigation. CTCs were identified through sequential gating steps, including EpCAM+ and high-SSC cells, cytokeratin positivity, and CD45-, HLA-A, B and C+ expression.
Based on these findings, EGFR (search) tyrosine kinase inhibitor erlotinib was added to the treatment regimen. Within two months, significant improvements were observed: AFP levels decreased from 3,880 to 294 ng/dl, CTC counts dropped from 23 to 782 cells/2.5 × 10⁵ PBMCs, and follow-up chest CT scan showed partial response.
Sequential EGFR Inhibitor Therapy
When AFP levels increased from 294 to 477 ng/dl, treatment was switched to afatinib, with anti-PD-1 (search) therapy (nivolumab) and continued lenvatinib. As AFP levels continued rising to 1,470 ng/dl, osimertinib replaced afatinib in April 2022, resulting in notable AFP decline from 10,067 to 2,265 ng/dl over five months.
In September 2022, despite imaging showing regression of previous lesions, new lesions appeared alongside rising AFP levels (2,265 to 3,484 ng/dl) and increased CTC count (98 to 782 cells/1×10⁶ PBMCs). A four-drug combination therapy consisting of osimertinib, lenvatinib, nivolumab, and ipilimumab was initiated, maintaining tumor stability until March 2023.
Clinical Significance and EGFR in HCC
The patient benefited from EGFR (search)-TKI treatment for 14 months with only grade 1 dermatosis reported as adverse effect. EGFR upregulation occurs in approximately 66% of HCC (search) cases and has been associated with tumorigenesis, aggressive tumor behavior, metastasis, and poor patient survival.
However, objective response rates of EGFR (search) inhibitors against HCC (search) typically range from 6.6% to 30%. Several factors explain this limited efficacy: the low prevalence of canonical sensitizing EGFR mutations in HCC, intratumoral heterogeneity and clonal diversity, and compensatory activation of parallel signaling pathways such as PI3K/AKT and MAPK/ERK.
CTC Analysis Advantages
HCC (search) diagnosis often relies on imaging techniques due to bleeding risk and tumor cell seeding from tissue biopsies, preventing comprehensive tumor biology research and limiting biomarker-driven precision medicine development. CTCs offer a valuable alternative to invasive biopsies for analyzing tumor genomics.
Previous studies have shown that mutation-specific antibodies demonstrate high specificity (99.0% and 89.7% for E746-A750 deletion and L858R mutation, respectively) in detecting EGFR (search) mutations, though sensitivity remains lower (70.6% and 80.4%, respectively).
Study Limitations and Future Directions
The researchers acknowledge limitations in their approach. While the patient presented with EGFR (search)-mutant CTCs and showed favorable response to EGFR TKIs, molecular-based EGFR mutation profiling of tumor biopsy was not performed. This decision was influenced by EGFR mutations' exceptionally low frequency (~2%) in HCC (search), high spatial intratumoral heterogeneity (5.21% to 88.27%), and lack of insurance reimbursement for such testing in Taiwan.
The clinical utility of EGFR (search) mutation profiling in HCC (search) is challenged by these factors, making CTC analysis particularly valuable for treatment selection in this patient population.
This case suggests that molecular information provided by CTCs may potentially guide personalized targeted therapy and prolong survival in patients with advanced HCC (search), offering a promising approach for precision oncology in this challenging malignancy.